This is a working overview of Dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-19 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
=== Early life === Major Force is a product of the same U.S. Federal project which created Captain Atom during the Vietnam War. The government, in a project headed by Wade Eiling and the scientist Megala, experiments with the effects of atomic energy on an alien metal to determine its full protective abilities such as protecting a human being from a nuclear blast. After Nathaniel Adam's disappearance and the perceived failure of the Captain Atom Project, the government restarts the project with a new test subject named Clifford Zmeck and increased the amount of metal used. While in the Air Force, Zmeck is imprisoned on charges of rape and murder and sentenced to life in prison. However, he is offered a pardon in exchange for participation in the high-risk governmental experiment. Zmeck disappears into the Quantum Field, emerging one year after the return of Nathaniel Adam with abilities similar to his.
Leukotrienes are members of a family of eicosanoid inflammatory mediators produced in leukocytes by the oxidation of arachidonic acid (AA) and the essential fatty acid eicosapentaenoic acid (EPA) by the enzyme arachidonate 5-lipoxygenase. Leukotrienes use lipid signaling to convey information to either the cell producing them (autocrine signaling) or neighboring cells (paracrine signaling) in order to regulate immune responses. The production of leukotrienes is usually accompanied by the production of histamine and prostaglandins, which also act as inflammatory mediators. The role of one type of leukotriene (specifically, leukotriene D4) is to trigger contractions in the smooth muscles lining the bronchioles; their overproduction is a major cause of inflammation in asthma and allergic rhinitis. Leukotriene antagonists are used to treat these disorders by inhibiting the production or activity of leukotrienes.
=== Link to cancer === Post-translational modification of proteins is a generally used mechanism in eukaryotic cell signaling. Ubiquitylation, ubiquitin conjugation to proteins, is a crucial process for cell cycle progression and cell proliferation and development. Although ubiquitylation usually serves as a signal for protein degradation through the 26S proteasome, it could also serve for other fundamental cellular processes, in endocytosis, enzymatic activation and DNA repair. Moreover, since ubiquitylation functions to tightly regulate the cellular level of cyclins, its misregulation is expected to have severe impacts. First evidence of the importance of the ubiquitin/proteasome pathway in oncogenic processes was observed due to the high antitumor activity of proteasome inhibitors. Various studies have shown that defects or alterations in ubiquitylation processes are commonly associated with or present in human carcinoma. Malignancies could be developed through loss of function mutation directly at the tumor suppressor gene, increased activity of ubiquitylation, and/or indirect attenuation of ubiquitylation due to mutation in related proteins.
On February 19, 2019, Sanders announced that he would seek the Democratic Party's 2020 nomination for president. He had declined the Vermont Democratic Party nomination for U.S. Senate in 2006, 2012, and 2018, which caused an unsuccessful legal challenge to his candidacy for the Democratic presidential nomination in 2016. Along with his 2019 campaign announcement, he said he would abide by a new Democratic Party rule for presidential candidates and that he would affirm his membership in that party. On March 5, 2019, he signed a formal statement, known as a "loyalty pledge", that he is a member of the Democratic Party and will serve as a Democrat if elected. News reports noted that the day before, he had signed paperwork to run as an independent for reelection to his Senate seat in 2024.
Sources: en.wikipedia.org
== Further reading == "Compolition of foods raw, processed, prepared" (PDF). United States Department of Agriculture. September 2015. Archived (PDF) from the original on October 31, 2016. Retrieved October 30, 2016.
In January 2026, Powell stated that the Department of Justice had served the Federal Reserve with grand jury subpoenas threatening a criminal indictment related to his congressional testimony about the renovation project. According to Powell, the subpoenas were issued on January 10, 2026. As of January 28, the Federal Reserve had reportedly not yet complied with the subpoenas; Powell declined to comment on the investigation at a press conference announcing the Federal Open Market Committee's interest rate decision that month. The investigation reportedly began in November 2025, and unnamed sources have said that Jeanine Pirro's office issued the subpoenas without contacting the White House, Attorney General Pam Bondi, or Deputy Attorney General Todd Blanche. Pirro has defended the investigation by asserting that the subpoenas were issued because the Federal Reserve did not respond to her office's requests to discuss the cost overruns of the renovation projects, asserting: "This office makes decisions based on the merits, nothing more and nothing less." A Justice Department spokesperson contacted about the investigation stated in a press release that Bondi "has instructed her U.S. Attorneys to prioritize investigating any abuse of taxpayer dollars", while Pirro stated in an interview: "We're talking about $1 billion in cost overruns in DC and something that is purely in my lane as the United States attorney to investigate".
One example, in which both plant and animal alkanes play a role, is the ecological relationship between the sand bee (Andrena nigroaenea) and the early spider orchid (Ophrys sphegodes); the latter is dependent for pollination on the former. Sand bees use pheromones in order to identify a mate; in the case of A. nigroaenea, the females emit a mixture of tricosane (C23H48), pentacosane (C25H52) and heptacosane (C27H56) in the ratio 3:3:1, and males are attracted by specifically this odor. The orchid takes advantage of this mating arrangement to get the male bee to collect and disseminate its pollen; parts of its flower not only resemble the appearance of sand bees but also produce large quantities of the three alkanes in the same ratio as female sand bees. As a result, numerous males are lured to the blooms and attempt to copulate with their imaginary partner: although this endeavor is not crowned with success for the bee, it allows the orchid to transfer its pollen, which will be dispersed after the departure of the frustrated male to other blooms.
Sources: en.wikipedia.org
Pratt (JP.1), it was entirely due to Collip's expertise that a far less toxic extract from that of Banting and Best's had been produced in just five weeks (p.288). Moreover, he was certain that, without Collip, the Toronto team would never have had an extract that was safe enough to administer to any human being. Also, according to Pratt (pp.286-288), the (pre-Collip) efforts of Banting and Best had been no improvement upon the work of George Ludwig Zuelzer fifteen years earlier: who, despite having been "on the right track" (in relation to recognizing the potential efficacy of a pancreatic extract in the treatment of diabetes mellitus) and, "even with the able assistance of the staff of the Physiological Institute of the University of Berlin as well as that of the trained chemists of the Schering Company over a period of four years [viz., prior to Zuelzer's 1907 publication], had been unable to lessen its toxicity sufficiently to have it employed clinically" (pp.286-288). By 22 February 1922, the Toronto team were reporting that "the effects observed in depancreatized animals have been paralleled in man", that the condition of seven patients had been "favourably influenced" by the daily injection of the extract, and that "the patients themselves report[ed] a subjective subjective sense of well being and increased vigor for a period following the [extract's] administration".
== History == 4-HO-NiPT was first described in the scientific literature, as a metabolite of 4-AcO-DiPT, in 2022. Subsequently, its synthesis was described in 2023 and its pharmacology was reported in 2024. The drug was reported as a possible novel designer drug online in 2022.
=== Antibacterial spectrum === Colistin has been effective in treating infections caused by Pseudomonas, Escherichia, and Klebsiella species. The following represents minimum inhibitory concentration (MIC) susceptibility data for a few medically significant microorganisms:
=== Non-human orthologs === Cathelicidin peptides have been found in humans, monkeys, mice, rats, rabbits, guinea pigs, pandas, pigs, cattle, frogs, sheep, goats, chickens, horses and wallabies. Antibodies to the human LL-37/hCAP-18 have been used to find cathelicidin-like compounds in a marsupial. About 30 cathelicidin family members have been described in mammals, with only one (LL-37) found in humans. Currently identified cathelicidin peptides include the following:
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.